BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 36125263)

  • 1. CD8+ and FoxP3+ T-Cell Cellular Density and Spatial Distribution After Programmed Death-Ligand 1 Check Point Inhibition.
    Curry J; Alnemri A; Philips R; Fiorella M; Sussman S; Stapp R; Solomides C; Harshyne L; South A; Luginbuhl A; Tuluc M; Martinez-Outschoorn U; Argiris A; Linnenbach A; Johnson J
    Laryngoscope; 2023 Aug; 133(8):1875-1884. PubMed ID: 36125263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin Effects on FOXP3
    Amin D; Richa T; Mollaee M; Zhan T; Tassone P; Johnson J; Luginbuhl A; Cognetti D; Martinez-Outschoorn U; Stapp R; Solomides C; Rodeck U; Curry J
    Laryngoscope; 2020 Sep; 130(9):E490-E498. PubMed ID: 31593308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
    Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
    J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin Clinical Trial in HPV+ and HPV- Head and Neck Squamous Cell Carcinoma: Impact on Cancer Cell Apoptosis and Immune Infiltrate.
    Curry JM; Johnson J; Mollaee M; Tassone P; Amin D; Knops A; Whitaker-Menezes D; Mahoney MG; South A; Rodeck U; Zhan T; Harshyne L; Philp N; Luginbuhl A; Cognetti D; Tuluc M; Martinez-Outschoorn U
    Front Oncol; 2018; 8():436. PubMed ID: 30364350
    [No Abstract]   [Full Text] [Related]  

  • 6. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
    Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
    Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
    Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
    Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8
    Hladíková K; Koucký V; Bouček J; Laco J; Grega M; Hodek M; Zábrodský M; Vošmik M; Rozkošová K; Vošmiková H; Čelakovský P; Chrobok V; Ryška A; Špíšek R; Fialová A
    J Immunother Cancer; 2019 Oct; 7(1):261. PubMed ID: 31623665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
    Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
    J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of HPV status on immune responses in head and neck squamous cell carcinoma.
    Qureshi HA; Zhu X; Yang GH; Steadele M; Pierce RH; Futran ND; Lee SM; Méndez E; Houghton AM
    Oral Oncol; 2022 Apr; 127():105774. PubMed ID: 35219073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
    Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
    Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tertiary Lymphoid Structure Raises Survival and Immunotherapy in HPV
    Li H; Zhu SW; Zhou JJ; Chen DR; Liu J; Wu ZZ; Wang WY; Zhang MJ; Sun ZJ
    J Dent Res; 2023 Jun; 102(6):678-688. PubMed ID: 36883630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
    Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
    Front Immunol; 2021; 12():798424. PubMed ID: 35145511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peritumoral cuffing by T-cell tumor-infiltrating lymphocytes distinguishes HPV-related oropharyngeal squamous cell carcinoma from oral cavity squamous cell carcinoma.
    Poropatich K; Hernandez D; Fontanarosa J; Brown K; Woloschak G; Paintal A; Raparia K; Samant S
    J Oral Pathol Med; 2017 Nov; 46(10):972-978. PubMed ID: 28632936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive T-cell immunophenotyping and next-generation sequencing of human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinomas.
    Poropatich K; Fontanarosa J; Swaminathan S; Dittmann D; Chen S; Samant S; Zhang B
    J Pathol; 2017 Nov; 243(3):354-365. PubMed ID: 28771750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors.
    de Ruiter EJ; de Roest RH; Brakenhoff RH; Leemans CR; de Bree R; Terhaard CHJ; Willems SM
    Cancer Immunol Immunother; 2020 Apr; 69(4):581-591. PubMed ID: 31980916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of immune makers with HPV 16 infections and the prognosis in oropharyngeal squamous cell carcinoma.
    Zhu Y; Zhu X; Diao W; Liang Z; Gao Z; Chen X
    Clin Oral Investig; 2023 Apr; 27(4):1423-1433. PubMed ID: 36884083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A digital score of tumour-associated stroma infiltrating lymphocytes predicts survival in head and neck squamous cell carcinoma.
    Shaban M; Raza SEA; Hassan M; Jamshed A; Mushtaq S; Loya A; Batis N; Brooks J; Nankivell P; Sharma N; Robinson M; Mehanna H; Khurram SA; Rajpoot N
    J Pathol; 2022 Feb; 256(2):174-185. PubMed ID: 34698394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments.
    Outh-Gauer S; Morini A; Tartour E; Lépine C; Jung AC; Badoual C
    Head Neck Pathol; 2020 Jun; 14(2):330-340. PubMed ID: 32124416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV infection related immune infiltration gene associated therapeutic strategy and clinical outcome in HNSCC.
    Zeng H; Song X; Ji J; Chen L; Liao Q; Ma X
    BMC Cancer; 2020 Aug; 20(1):796. PubMed ID: 32831060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.